Tiziana Life Sciences Ltd. announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab in its Expanded Access Program (EAP). Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer?s disease, and amyotrophic lateral sclerosis, or ALS.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.679 USD | -12.96% | -9.09% | +22.34% |
Apr. 23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
Apr. 23 | Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+22.34% | 78.25M | |
+2.34% | 42.75B | |
+47.70% | 41.61B | |
+11.94% | 41.34B | |
-12.36% | 26.59B | |
+8.70% | 25.49B | |
-22.96% | 18.12B | |
+30.86% | 12.24B | |
-1.45% | 11.76B | |
+8.48% | 11B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS)